{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025242","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.600225+00:00","generated_at":"2026-05-17T17:45:32.223599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"UroGen reports Q2 loss of $49.9M; launches ZUSDURI after June FDA approval","bullets":["ZUSDURI (mitomycin) FDA-approved June 12 for recurrent LG-IR-NMIBC; now commercially available.","JELMYTO Q2 net revenue $24.2M (+11% vs Q2 2024); FY guidance $94-98M unchanged.","Net loss $49.9M ($1.05/share) vs $33.4M ($0.82) in Q2 2024; operating loss $41.4M.","Cash and marketable securities $161.6M at June 30, 2025.","Enrollment complete in Phase 3 UTOPIA trial for next-gen mitomycin UGN-103."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025242","json":"https://secwatch.observer/filing/0001437749-25-025242.json","markdown":"https://secwatch.observer/filing/0001437749-25-025242.md","text":"https://secwatch.observer/filing/0001437749-25-025242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/0001437749-25-025242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/urgn20250804_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:45:32.223599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}